Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio
REYKJAVIK, Iceland, June 8, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global…
Novartis to highlight Rhapsido data across multiple immune-mediated diseases at EAACI Congress 2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study…
Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems
Eversense 365 delivered favorable glucometrics compared to other open and closed loop…
Vireo Growth Inc. Completes Acquisition of Bridgewell Agribusiness LLC and Plans to Acquire Dispensaries in Nevada and Maryland
MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO)…
Premier Health of America Announces Grant of Management Cease Trade Order
MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC.…
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation…
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist…
Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial A
June 05, 2026 19:30 ET | Source: Oban BioPharma, Inc. STAMFORD, Conn.,…
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and…
